These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 35219127)

  • 1. Assessing humoral immune response after two doses of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers.
    Demirbakan H; Koçer I; Erdoğan M; Bayram A
    Public Health; 2022 Apr; 205():1-5. PubMed ID: 35219127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers.
    Bayram A; Demirbakan H; Günel Karadeniz P; Erdoğan M; Koçer I
    J Med Virol; 2021 Sep; 93(9):5560-5567. PubMed ID: 34019704
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dynamic of anti-spike receptor binding domain (RBD) levels and short-term adverse events following a heterologous booster dose of BNT162b2 after two doses of CoronaVac in Thai health care workers.
    Kitro A; Sirikul W; Thongkum W; Soponpong S; Yasamut U; Kiratipaisarl W; Kosai A; Kasinrerk W; Tayapiwatana C; Srithanaviboonchai K
    Vaccine; 2022 May; 40(21):2915-2924. PubMed ID: 35430106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Investigation of SARS-CoV-2-Specific Humoral and Cellular Immunity Values in Health Care Workers with COVID-19 Disease and Administered with COVID-19 Vaccine].
    Keskin AÜ; Dalan AB; Çıragil P; Topkaya AE
    Mikrobiyol Bul; 2022 Jul; 56(3):480-492. PubMed ID: 35960239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inactive SARS-CoV-2 vaccine generates high antibody responses in healthcare workers with and without prior infection.
    Dinc HO; Saltoglu N; Can G; Balkan II; Budak B; Ozbey D; Caglar B; Karaali R; Mete B; Tuyji Tok Y; Ersoy Y; Ahmet Kuskucu M; Midilli K; Ergin S; Kocazeybek BS
    Vaccine; 2022 Jan; 40(1):52-58. PubMed ID: 34839992
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SARS-CoV-2 specific antibody responses in healthcare workers after a third booster dose of CoronaVac or BNT162b2 vaccine.
    Yavuz E; Günal Ö; Başbulut E; Şen A
    J Med Virol; 2022 Aug; 94(8):3768-3775. PubMed ID: 35434796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The Second Shot of CoronaVac Vaccine May Cause Reduction of Antibody Levels in People who Previously had COVID-19].
    Topkaya AE; Keskin AÜ; Dalan AB; Çıragil P
    Mikrobiyol Bul; 2022 Jan; 56(1):139-142. PubMed ID: 35088968
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Antibody Response After Two Doses of Inactivated SARS-CoV-2 Vaccine in Healthcare Workers with and without Previous COVID-19 Infection: A Prospective Observational Study].
    Özgür D; Tütüncü EE
    Mikrobiyol Bul; 2022 Jan; 56(1):36-48. PubMed ID: 35088958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Investigation of Humoral and Cellular Immunity in TOBB ETÜ Hospital Workers After Three Doses of CoronaVac Vaccination and after One Dose of Comirnaty Vaccination Following Two Doses of CoronaVac].
    Özyurda F; Ardıçoğlu Akışın Y; Mert T; Poyraz B; Özkan Y; Turan M; Göçmen JS; Yücel A; Akar N
    Mikrobiyol Bul; 2022 Jul; 56(3):387-403. PubMed ID: 35960233
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Waning immunity to inactive SARS-CoV-2 vaccine in healthcare workers: booster required.
    Balkan İİ; Dinc HO; Can G; Karaali R; Ozbey D; Caglar B; Beytur AN; Keskin E; Budak B; Aydogan O; Mete B; Ergin S; Kocazeybek B; Saltoglu N
    Ir J Med Sci; 2023 Feb; 192(1):19-25. PubMed ID: 35344137
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of immunogenicity and reactogenicity of inactivated SARS-CoV-2 vaccine (CoronaVac) in previously SARS-CoV-2 infected and uninfected health care workers.
    Soysal A; Gönüllü E; Karabayır N; Alan S; Atıcı S; Yıldız İ; Engin H; Çivilibal M; Karaböcüoğlu M
    Hum Vaccin Immunother; 2021 Nov; 17(11):3876-3880. PubMed ID: 34324409
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Durability of COVID-19 humoral immunity post infection and different SARS-COV-2 vaccines.
    Alroqi F; Barhoumi T; Masuadi E; Nogoud M; Aljedaie M; Abu-Jaffal AS; Bokhamseen M; Saud M; Hakami M; Arabi YM; Nasr A
    J Infect Public Health; 2024 Apr; 17(4):704-711. PubMed ID: 38479067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Humoral Immune Response in Inactivated SARS-CoV-2 Vaccine: When Should a Booster Dose be Administered?].
    Kara E; Tanır F; Demirhindi H; Mete B; Kibar F; Çetiner S; Candevir A; İnaltekin A
    Mikrobiyol Bul; 2022 Jul; 56(3):566-573. PubMed ID: 35960246
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
    Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
    Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antibody response after a third dose mRNA-1273 vaccine among vaccinated healthcare workers with two doses of inactivated SARS-CoV-2 vaccine.
    Cucunawangsih C; Wijaya RS; Lugito NPH; Suriapranata I
    Int J Infect Dis; 2022 May; 118():116-118. PubMed ID: 35192955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
    Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
    BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
    Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
    BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Humoral response to the SARS-CoV-2 BNT162b2 mRNA vaccine: Real-world data from a large cohort of healthcare workers.
    Oliveira-Silva J; Reis T; Lopes C; Batista-Silva R; Ribeiro R; Marques G; Pacheco V; Rodrigues T; Afonso A; Pinheiro V; Araújo L; Rodrigues F; Antunes I
    Vaccine; 2022 Jan; 40(4):650-655. PubMed ID: 34952755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Status of Humoral and Cellular Immune Responses within 12 Months following CoronaVac Vaccination against COVID-19.
    Zhao W; Chen W; Li J; Chen M; Li Q; Lv M; Zhou S; Bai S; Wang Y; Zhang L; Zhang P; Wang J; Zheng Q; Wu J
    mBio; 2022 Jun; 13(3):e0018122. PubMed ID: 35475648
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial.
    Chen GL; Li XF; Dai XH; Li N; Cheng ML; Huang Z; Shen J; Ge YH; Shen ZW; Deng YQ; Yang SY; Zhao H; Zhang NN; Zhang YF; Wei L; Wu KQ; Zhu MF; Peng CG; Jiang Q; Cao SC; Li YH; Zhao DH; Wu XH; Ni L; Shen HH; Dong C; Ying B; Sheng GP; Qin CF; Gao HN; Li LJ
    Lancet Microbe; 2022 Mar; 3(3):e193-e202. PubMed ID: 35098177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.